linjc16/ctgov huggingface dataset:
Bismuth for PCAB-based H. Pylori Eradication

Study Overview
=================
Brief Summary
-----------------
Tegoprazan is a new potassium-competitive acid blocker (PCAB) that has been clinically available since 2018 in South Korea. P-CAB is highly active drugs targeting H+, K+ -ATPase in the gastric acid secretion of parietal cells. The mechanism of action is different from that of PPIs. Conventional PPIs require 3-5 days to achieve maximal and steady-state gastric acid inhibition, whereas P-CAB increases the intragastric pH to nearly 7 within four hours. In Japan, H. pylori eradication success rates has increased by therapies using P-CAB than those using proton pump inhibitors, owing to the stronger acid suppression capability of P-CAB. Bismuth has long been used to treat peptic ulcer disease, dyspepsia, parasite infections, and infectious diarrhea. The antibacterial effects of bismuth include inhibition of protein and cell wall synthesis in H. pylori. The main role of bismuth is to increase the eradication rate by 30%-40% in resistant H. pylori strains.

Detailed Description
-----------------
The investigators aim to evaluate the success rate and adverse drug events of bismuth added to PCAB-based triple therapy as a first-line regimen for H. pylori infection.

Official Title
-----------------
Efficacy of Bismuth Added to Potassium-competitive Acid Blocker-based Triple Regimen for First-line Helicobacter Pylori Eradication

Conditions
-----------------
H. Pylori Infection

Intervention / Treatment
-----------------
* Drug: H. pylori eradication


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gastroscopy can be performed H. pylori test and pathological analysis can be performed Exclusion Criteria: Age < 20 or > 80 years Anemia (serum hemoglobin level < 10 g/dL) Severe systemic disease Advanced chronic liver disease Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics History of H. pylori eradication Drug allergy to antibiotics History of gastric surgery Recent history of upper gastrointestinal bleeding

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-bismuth group<br>Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days | Drug: H. pylori eradication<br>* PPIs-based Antimicrobial agents for H. pylori eradication<br>|
| Bismuth group<br>Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days | Drug: H. pylori eradication<br>* PPIs-based Antimicrobial agents for H. pylori eradication<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| H. pylori infection status | Rate of successful H. pylori eradication | 6 weeks |
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Study Overview
=================
Brief Summary
-----------------
Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. Cathepsin G is known to activate Il- 36 and promote inflammation in psoriasis.NB-UVB is one of the important treatment modalities for psoriasis. The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in psoriasis.

Detailed Description
-----------------
25 psoriasis patients will receive 26 sessions of phototherapy (NB-UVB). Patients will receive 3 sessions per week. Tissue levels of IL-36 and Cathepsin G will be assessed in skin lesions before starting treatment and after completing the 26 sessions.

Official Title
-----------------
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis Lesional Skin

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Device: NB-UVB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with psoriasis vulgaris of both sexes Age between 18 and 60 years old. Exclusion Criteria: Pregnant females Patients receiving systemic treatment or topical treatment for psoriasis within the past two months. Patients having other dermatological diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: nb-uvb<br>psoriasis patients will receive 26 sessions of nb-uvb phototherapy | Device: NB-UVB<br>* Phototherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in Il-36 levels in 25 psoriasis patients after 26 sessions of NB-UVB | primary | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in cathepsin G levels in 25 psoriasis patients after 26 sessions of NB-UVB psoriasis | secondary | 6 months |
Mobile App in Addiction

Study Overview
=================
Brief Summary
-----------------
The sleep and behavior agendas are today very largely underused while they can be of a considerable contribution in the follow-up of the patients and the reinforcement of the therapeutic alliance. In the management of addictions, sleep disorders are a major comorbidity, these two components maintain indeed complex links: it was highlighted a bidirectional relationship between the effect of the consumption of addictive substances on sleep and conversely, the effect of sleep disorders on the consumption of products, the same is true for overexposure to screens.

Detailed Description
-----------------
The sleep and behavior agendas are today very largely underused while they can be of a considerable contribution in the follow-up of the patients and the reinforcement of the therapeutic alliance. In the management of addictions, sleep disorders are a major comorbidity, these two components maintain indeed complex links: it was highlighted a bidirectional relationship between the effect of the consumption of addictive substances on sleep and conversely, the effect of sleep disorders on the consumption of products, the same is true for overexposure to screens.

Official Title
-----------------
A Mobile App for the Self Quantification of Sleep and Behaviors : a Pilot Study With Teenagers and Young Adults

Conditions
-----------------
Addiction

Intervention / Treatment
-----------------
* Device: ASC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Teenagers or young adults from 12 to 18 years old (included) Consultant for addiction to cannabis and / or tobacco and / or alcohol and / or screen Treated within the Functional Unit of addictology For minors, after parental consent Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mobile application (ASC)<br>mobile app / devise | Device: ASC<br>* mobile app<br>* Other names: mobile application;|
| Active Comparator: Paper diary<br>paper diary | Device: ASC<br>* mobile app<br>* Other names: mobile application;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of days filled for sleep and consumptions, usable by the doctor on the day of the consultation / after 15 days of self-evaluation required by the treatment |  | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mobile app, pilot study, addiction, sleep, ePRO
Measurement of Exhaled Propofol

Study Overview
=================
Brief Summary
-----------------
Propofol is a common intravenous anaesthetic drug used for anaesthesia induction and for permanent infusion to maintain anaesthesia (total intravenous anaesthesia). Different to the volatile anaesthetics (feedback concentrations in exhaled breathing gas) piloting of an total intravenous anaesthesia with propofol is done only by experience of the anaesthetist or according to pharmacokinetic models. In this study we want to investigate if the exhaled fraction of propofol is a potential measurement parameter for piloting anaesthesia. Exhaled propofol will be measured with an electrochemical sensor developed by Drägerwerk AG & Co. KGaA. Exhaled propofol levels will be compared with the corresponding arterial serum concentrations of propofol. Furthermore we investigate the correlation of exhaled propofol levels with the Bispectral Index (BIS).

Official Title
-----------------
Measurement of Exhaled Propofol During a Total Intravenous Anesthesia With Propofol and Remifentanil

Conditions
-----------------
Anaesthesia With Propofol

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA (American Society of Anaesthesiologists) classification I & II Body-Mass-Index < 35 elective surgery with the necessity of an arterial catheter Exclusion Criteria: chronic obstructive lung disease bronchial asthma smokers with more than 5 packyears peripheral artery occlusive disease diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| exhaled propofol levels in breathing gas |  | continous recording during the whole anaesthesia (duration depents on surgery, between 2 and 12 hours) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| propofol concentration in arterial blood serum |  | samples taken during anaesthesia (13 blood samples), duration of anaesthesia depends on surgery, 2 to 12 hours | 
| Bispectral Index (BIS) |  | continous recording during the whole anaesthesia (duration depents on surgery, between 2 and 12 hours) |
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Study Overview
=================
Brief Summary
-----------------
This study has the objective of providing compassionate use access to omalizumab (Xolair) and to evaluate the Safety of Xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to GINA step 4 treatment guidelines.

Official Title
-----------------
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Biological: omalizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female, ≥ 6years of age; who have a diagnosis of allergic asthma ≥ 1 year duration according to American Thoracic Society (ATS) criteria; severe persistent allergic asthma who remain symptomatic despite optimal therapy (as per Canadian Asthma Consensus Report (1999)); Subjects having successfully completed one of the following protocols: CIGE025A011E3, CIGE025A2425, CIGE025AIA05; elevated immunoglobin E levels Exclusion Criteria: significant systemic disease pregnancy or lactation an active lung disease other than allergic asthma (eg: cystic fibrosis, bronchiestasis); history of food or drug related severe anaphylactoid or anaphylactic reaction(s); current treatment with warfarin (Coumadin®), immunomodulatory therapy (e.g., methotrexate, gold, cyclosporine), or antiplatelet therapy.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Biological: omalizumab<br>* sc<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serious Adverse Events from first visit until end of study |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate reasons for premature discontinuation. |  |  | 
| All adverse events, duration of study participation. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Anti-immunoglobin E, omalizumab
Decision Making in Video Games

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether anodal transcranial direct current stimulation (tDCS) applied to the left dorsolateral prefrontal cortex induces approach motivation, and whether anodal tDCS applied to the right dorsolateral prefrontal cortex induces avoidance motivation. This study consists of three experiments: one in which an approach/avoidance video game is validated, one in which the effect of anger and fear on approach/avoidance is studied, and one in which the effect of tDCS is studied. Only the experiment in which the effect of tDCS is studied involves tDCS.

Official Title
-----------------
Decision Making in Video Games

Conditions
-----------------
Cognitive Change

Intervention / Treatment
-----------------
* Device: Anodal left dorsolateral prefrontal cortex tDCS stimulation
* Device: Anodal right dorsolateral prefrontal cortex tDCS stimulation
* Device: Sham tDCS stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal hearing and vision Exclusion Criteria: Left-handedness History of seizure, head injury (including neurosurgery), brain injury, diagnosis or a neurological or psychiatric disorder, metal in the head, sensitive scalp History of anxiolytic and/or antidepressant medications Participation in Experiment #1 or Experiment #2 of the larger study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Anodal left dorsolateral prefrontal cortex tDCS stimulation<br> | Device: Anodal left dorsolateral prefrontal cortex tDCS stimulation<br>* Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants<br>|
| Experimental: Anodal right dorsolateral prefrontal cortex tDCS stimulation<br> | Device: Anodal right dorsolateral prefrontal cortex tDCS stimulation<br>* Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants<br>|
| Sham Comparator: Sham tDCS stimulation<br> | Device: Sham tDCS stimulation<br>* Sham tDCS stimulation will be applied<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Avoidance-Approach time difference | Median of the difference between time to approach and time to avoid a stimulus | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
approach motivation, avoidance motivation, transcranial direct current stimulation
Hallux Valgus Conservative Treatment

Study Overview
=================
Brief Summary
-----------------
Studying the effect of kinesiotape on hallux valgus angle and pain in hallux valgus patients.

Detailed Description
-----------------
30 patients (male and female) suffering from bilateral Halux valgus. Divided randomly into 2 groups st group receive kinesiotape bilaterally for correction : Hallux valgus angle (HVA) was measured using Xray and pain was measured using VAS before applying tape and after 8 weeks of tape application. nd group receive placebo tape bilaterally and had the same measurements. 2 groups were on a group of exercises

Official Title
-----------------
Influence of Short-Term Conservative Treatment Using Kinesiotape on Hallux Valgus Angle

Conditions
-----------------
Hallux Valgus

Intervention / Treatment
-----------------
* Other: Kinesiotape


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mobile hallux valgus Exclusion Criteria: using orthotics knee malalignment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Pretest and posttest Control group randomized control trial
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental kinesiotape group A<br>Kinesiotape group | Other: Kinesiotape<br>* Elastic tape used for mechanical correction of the deformity in study group and placebo in control group<br>|
| Placebo Comparator: Placebo kinesiotape group B<br>Control group | Other: Kinesiotape<br>* Elastic tape used for mechanical correction of the deformity in study group and placebo in control group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hallux valgus angle (HVA ) | Hallux valgus angle measured by x ray | 8 weeks | 
| Pain on metatarsophalangeal joint measured by visual analogue scale (VAS) |  | 8 weeks |
Triglyceride/High-density Lipoprotein Cholesterol Ratio in Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
The Triglycerides (TG) to High Density Lipoprotein Cholesterol (HDL-C) ratio is a feature of insulin resistance and an independent predictor of cardiovascular risk. The investigators aimed to evaluate the relationship between TG/HDL-C ratio and the endothelial functions in patients with CKD.

Detailed Description
-----------------
Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease (CKD).The reasons for the elevated risk of CVD in patients with CKD are not fully elucidated. There is not a good prognostic tool for the prediction of increased cardiovascular risk in CKD. A simple, widely available, relatively inexpensive, and generally reproducible marker to predict the CVD risk in subjects with CKD is needed. The Triglycerides (TG) to High Density Lipoprotein Cholesterol (HDL-C) ratio is a feature of insulin resistance and an independent predictor of cardiovascular risk. No study has been performed so far, to evaluate the role of TG/HDL ratio to predict the CVD risk in patients with CKD. This study is designed to evaluate the relationship between TG/HDL-C ratio and the endothelial functions in patients with CKD.

Official Title
-----------------
The Prospective Cohort Study to Investigate the Role of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio To Predict Cardiovascular Outcomes in Chronic Kidney Disease.

Conditions
-----------------
Chronic Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with chronic kidney disease Exclusion Criteria: taking drugs that may influence endothelial function acute infections

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality | The COX analysis was performed in order to establish which covariates were independent predictors of cardiovascular outcomes. Kaplan Meier survival curves are generated to show the impact of the TG/HDL ratio on the cumulative survival of the cohort. The predictive power of the median TG/HDL ratio in each CKD stage for all-cause mortality and cardiovascular events are measured. | 30 months | 
| Endothelial functions assessed by flow mediated dilatation and serum ADMA measurement | The predictive role of TG/HDL ratio on endothelial functions (ADMA and flow mediated dilatation) is determined by univariate and multivariate analyses. | Once in recruitment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic kidney disease, Endothelial dysfunction, Inflammation, Insulin resistance, Tg/hdl ratio